<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1915">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136235</url>
  </required_header>
  <id_info>
    <org_study_id>PiEP study</org_study_id>
    <nct_id>NCT05136235</nct_id>
  </id_info>
  <brief_title>Pulmonary Hypertension in Extremely Preterm Infants</brief_title>
  <acronym>PiEP</acronym>
  <official_title>Pulmonary Hypertension in Extremely Preterm Infants - A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GZA Ziekenhuizen Campus Sint-Augustinus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extremely preterm infants are at risk for developing bronchopulmonary dysplasia (BPD) and&#xD;
      associated chronic pulmonary hypertension (PH), a consequence of altered pulmonary&#xD;
      vasculature. This condition occurs in about 25% of babies with BPD, and the association grows&#xD;
      with increasing BPD severity. Other risk factors have been described as well. Morbidity and&#xD;
      mortality associated with prematurity and/or BPD increase significantly in the presence of&#xD;
      PH.&#xD;
&#xD;
      Thus, international guidelines encourage the use of standardized screening protocols for this&#xD;
      condition. However, several questions regarding these recommendations are left unanswered,&#xD;
      such as a clear definition for PH in this population.&#xD;
&#xD;
      The research aim is to prospectively evaluate prevalence, risk factors and clinical course of&#xD;
      PH in these children. The investigators aim to identify at-risk infants early on and&#xD;
      ultimately improve survival making use of an early targeted intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of pulmonary hypertension</measure>
    <time_frame>3-10 days of life (time depending on the timing of the first echocardiography)</time_frame>
    <description>Pulmonary hypertension will be defined as one or more of the following echocardiographic findings:&#xD;
Presence of a cardiac shunt with bidirectional or right-to-left flow&#xD;
Estimated right ventricular systolic pressure (RVSP) &gt;40 mmHg&#xD;
RVSP/systemic systolic blood pressure (SBP) ratio &gt;0.5&#xD;
Presence of ventricular septal wall flattening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of pulmonary hypertension</measure>
    <time_frame>at 28 days of life</time_frame>
    <description>Pulmonary hypertension will be defined as one or more of the following echocardiographic findings:&#xD;
Presence of a cardiac shunt with bidirectional or right-to-left flow&#xD;
Estimated right ventricular systolic pressure (RVSP) &gt;40 mmHg&#xD;
RVSP/systemic systolic blood pressure (SBP) ratio &gt;0.5&#xD;
Presence of ventricular septal wall flattening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of pulmonary hypertension</measure>
    <time_frame>at 36 weeks PMA</time_frame>
    <description>Pulmonary hypertension will be defined as one or more of the following echocardiographic findings:&#xD;
Presence of a cardiac shunt with bidirectional or right-to-left flow&#xD;
Estimated right ventricular systolic pressure (RVSP) &gt;40 mmHg&#xD;
RVSP/systemic systolic blood pressure (SBP) ratio &gt;0.5&#xD;
Presence of ventricular septal wall flattening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of pulmonary hypertension</measure>
    <time_frame>at 6 months of age</time_frame>
    <description>Pulmonary hypertension will be defined as one or more of the following echocardiographic findings:&#xD;
Presence of a cardiac shunt with bidirectional or right-to-left flow&#xD;
Estimated right ventricular systolic pressure (RVSP) &gt;40 mmHg&#xD;
RVSP/systemic systolic blood pressure (SBP) ratio &gt;0.5&#xD;
Presence of ventricular septal wall flattening</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of pulmonary hypertension</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>Pulmonary hypertension will be defined as one or more of the following echocardiographic findings:&#xD;
Presence of a cardiac shunt with bidirectional or right-to-left flow&#xD;
Estimated right ventricular systolic pressure (RVSP) &gt;40 mmHg&#xD;
RVSP/systemic systolic blood pressure (SBP) ratio &gt;0.5&#xD;
Presence of ventricular septal wall flattening</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of bronchopulmonary dysplasia</measure>
    <time_frame>at 28 days of life</time_frame>
    <description>Assessment of supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of bronchopulmonary dysplasia</measure>
    <time_frame>at 36 weeks PMA</time_frame>
    <description>Classification of BPD with an oxygen reduction test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>at birth</time_frame>
    <description>Birth weight in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age</measure>
    <time_frame>at birth</time_frame>
    <description>Gestational age in weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age</measure>
    <time_frame>at birth</time_frame>
    <description>Birth weight &lt;P3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oligohydramnios</measure>
    <time_frame>at birth</time_frame>
    <description>Presence of oligohydramnios during pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal hypertensive disorders</measure>
    <time_frame>at birth</time_frame>
    <description>Presence of maternal hypertensive disorders during pregnancy (pre-eclampsia, hypertension, HELLP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROP</measure>
    <time_frame>at 36 weeks</time_frame>
    <description>Presence of retinopathy of prematurity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEC</measure>
    <time_frame>at 36 weeks</time_frame>
    <description>Presence of necrotizing enterocolitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PDA</measure>
    <time_frame>at 36 weeks</time_frame>
    <description>Presence of patent ductus arteriosus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>up to discharge from the NICU, an average of 16 weeks</time_frame>
    <description>Presence of sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAP</measure>
    <time_frame>at 36 weeks</time_frame>
    <description>Presence of ventilator associated pneumonia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>Extremely preterm newborns</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All extremely preterm newborns in Flanders will be included, it is a single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period</description>
    <arm_group_label>Extremely preterm newborns</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NT-proBNP</intervention_name>
    <description>At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample</description>
    <arm_group_label>Extremely preterm newborns</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Preterm infants with&#xD;
&#xD;
          -  Gestational age &lt;28 0/7 weeks&#xD;
&#xD;
          -  Birth weight &lt;1000 grams&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major congenital malformations&#xD;
&#xD;
          -  Structural airway or lung disease&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Lack of parental consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara De Bisschop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip Cools, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniël De Wolf, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara De Bisschop, MD</last_name>
    <phone>0032 2 477 77 21</phone>
    <email>barbara.debisschop@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Arjaans S, Zwart EAH, Ploegstra MJ, Bos AF, Kooi EMW, Hillege HL, Berger RMF. Identification of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: A systematic review and meta-analysis. Paediatr Perinat Epidemiol. 2018 May;32(3):258-267. doi: 10.1111/ppe.12444. Epub 2018 Jan 17. Review.</citation>
    <PMID>29341209</PMID>
  </reference>
  <reference>
    <citation>Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; and the American Thoracic Society. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015 Nov 24;132(21):2037-99. doi: 10.1161/CIR.0000000000000329. Epub 2015 Nov 3. Erratum in: Circulation. 2016 Jan 26;133(4):e368.</citation>
    <PMID>26534956</PMID>
  </reference>
  <reference>
    <citation>Hilgendorff A, Apitz C, Bonnet D, Hansmann G. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart. 2016 May;102 Suppl 2:ii49-56. doi: 10.1136/heartjnl-2015-308591.</citation>
    <PMID>27053698</PMID>
  </reference>
  <reference>
    <citation>Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, Hanna B, Romer L, Keller RL, Fineman J, Steinhorn R, Kinsella JP, Ivy DD, Rosenzweig EB, Raj U, Humpl T, Abman SH; Pediatric Pulmonary Hypertension Network (PPHNet). Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia. J Pediatr. 2017 Sep;188:24-34.e1. doi: 10.1016/j.jpeds.2017.05.029. Epub 2017 Jun 20. Review.</citation>
    <PMID>28645441</PMID>
  </reference>
  <reference>
    <citation>Levy PT, Jain A, Nawaytou H, Teitel D, Keller R, Fineman J, Steinhorn R, Abman SH, McNamara PJ; Pediatric Pulmonary Hypertension Network (PPHNet). Risk Assessment and Monitoring of Chronic Pulmonary Hypertension in Premature Infants. J Pediatr. 2020 Feb;217:199-209.e4. doi: 10.1016/j.jpeds.2019.10.034. Epub 2019 Nov 14. Review.</citation>
    <PMID>31735418</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

